Supplementary Figure 3 from Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial

MLA

Amy B. Heimberger, et al. Supplementary Figure 3 from Glioblastoma-Mediated Immune Dysfunction Limits CMV-Specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial. Mar. 2023. EBSCOhost, https://doi.org/10.1158/1078-0432.22475450.v1.

APA

Amy B. Heimberger, Katayoun Rezvani, Elizabeth J. Shpall, Raymond Sawaya, Frederick F. Lang, Jeffrey S. Weinberg, Ganesh Rao, Linda Chi, Jason T. Huse, Gregory N. Fuller, Carlos Kamiya-Matsuoka, Nazanin Majd, Rebecca Harrison, Barbara J. O’Brien, John F. de Groot, Mayra Shanley, Abdullah Alsuliman, Hila Shaim, Mustafa Bdiwi, … Shiao-Pei Weathers. (2023). Supplementary Figure 3 from Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial. https://doi.org/10.1158/1078-0432.22475450.v1

Chicago

Amy B. Heimberger, Katayoun Rezvani, Elizabeth J. Shpall, Raymond Sawaya, Frederick F. Lang, Jeffrey S. Weinberg, Ganesh Rao, et al. 2023. “Supplementary Figure 3 from Glioblastoma-Mediated Immune Dysfunction Limits CMV-Specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial,” March. doi:10.1158/1078-0432.22475450.v1.